Ocrevus 300 mg

Ocrevus (ocrelizumab) is used to treat:

• Relapsing forms of multiple sclerosis (RRMS)

• Primary progressive multiple sclerosis (PPMS)

It works by targeting CD20-positive B cells, a type of white blood cell involved in the abnormal immune response in MS. This helps reduce relapses and slow disability progression.

How to Use:
Administered via intravenous (IV) infusion in a medical facility.

• Initial dose: 300 mg given twice, two weeks apart

• Subsequent doses: 600 mg every 6 months

Common Side Effects:

• Infusion-related reactions (fever, rash, itching, headache)

• Upper respiratory tract infections

• Herpes virus infections

• Low white blood cell counts

Warnings:

• Screening for hepatitis B virus is required before starting treatment

• Monitor for infusion-related reactions during and after the infusion

• Use cautiously in patients with chronic infections or weakened immune system

• Not recommended during pregnancy or breastfeeding unless directed by a physician

• For use under medical supervision only